Autolus Therapeutics logo
Autolus Therapeutics
AUTL | NASDAQ
Chart Builder DCF Calculator
$1.16
-$0.01 (-0.85%)
At close: Nov 16, 2026, 3:59 PM ET
$1.14
-$0.02 (-1.72%)
After-hours: Nov 16, 2026, 7:39 PM ET

Autolus Therapeutics Company Profile

Company profile explained

Company Profile

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

Key Executives

Name Position
Christian Martin Itin Chief Executive Officer & Director
Christopher Vann Senior Vice President & Chief Operating Officer
Miranda Neville Senior VP & Chief Technology Officer
Robert F. Dolski Senior Vice President & Chief Financial Officer
Alex Driggs Senior Vice President of Legal Affairs & General Counsel and Secretary
Alexander Swan Senior Vice President & Chief Human Resources Officer
Chris Williams Senior VP & Chief Business Development Officer
Martin Pule MBBS Founder, Senior Vice President & Chief Scientific Officer
Matthias Will Senior Vice President & Chief Development Officer
Patrick McIlvenny Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer

Latest SEC Filings

Date Type Title
Sep 22, 2026 EFFECT Filing
Sep 22, 2026 424B3 Filing
Sep 15, 2026 DEL AM Filing
Sep 14, 2026 S-3 Filing
Sep 03, 2026 4 Filing
Aug 28, 2026 SC 13D/A [Amend] Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 11, 2026 10-Q Quarterly Report
Aug 11, 2026 8-K Current Report
Aug 03, 2026 8-K Current Report
View All SEC Filings ➞
Autolus Therapeutics
Autolus Therapeutics logo
Country United Kingdom
IPO Date Jun 22, 2018
Industry Biotechnology
Sector Healthcare
Employees 752
CEO Christian Martin Itin

Contact Details

The MediaWorks London, GL W12 7FP United Kingdom

Stock Details

Ticker Symbol AUTL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001730463
CUSIP Number 05280R100
ISIN Number US05280R1005
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.